Characterizing Prostate Cancer By ex vivo MRS Signatures
通过离体 MRS 特征表征前列腺癌
基本信息
- 批准号:7893739
- 负责人:
- 金额:$ 55.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-27 至 2013-03-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdenocarcinomaAdjuvant TherapyAffectAmericanBehaviorBenignBenign Prostatic HypertrophyBiochemicalBiologicalBiologyBiomedical EngineeringBiopsyBiopsy SpecimenCancer EtiologyCancer PatientCellsCessation of lifeChemicalsClinicalConsultationsDataDetectionDevelopmentDiagnosisDiagnosticDiagnostic Neoplasm StagingDiagnostic testsDiseaseEarly DiagnosisEngineeringEvaluationExploratory/Developmental Grant for Diagnostic Cancer ImagingGleason Grade for Prostate CancerGoalsHealth behaviorHistologicHistopathologyHumanIndividualInvestigationKnowledgeLaboratoriesMagicMagnetic Resonance SpectroscopyMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of prostateMeasurementMeasuresMetabolicMethodsModalityMorphologyNatureOperative Surgical ProceduresOutcomePSA screeningPathological StagingPatientsPersonal SatisfactionPopulationProbabilityProstateProstate AdenocarcinomaProstatectomyProstatic Intraepithelial NeoplasiasProstatic NeoplasmsProtocols documentationProtonsRecurrent diseaseResearchResearch PersonnelResearch Project GrantsResolutionRiskSamplingSpecificitySpecimenStagingStructureSystemTechniquesTestingTissuesTreatment FailureUnited States National Institutes of Healthbasecancer carecancer diagnosisclinical practicecostexperiencehuman tissueimprovedin vivomenoutcome forecastpatient populationpreventprognosticsuccesstooltreatment planningtumor
项目摘要
DESCRIPTION (provided by applicant): For two decades, PSA testing has been employed routinely in clinical practice. The outstanding success of this approach, with its emphasis on early detection of malignancy, can be judged by one key distinction between today's prostate cancer patient population and that of 20 years ago: today, >70% of prostate cancer patients are diagnosed with asymptomatic, moderately differentiating adenocarcinomas. Despite this accomplishment, prostate cancer remains the second leading cause of cancer death among American men. The diversity of outcomes observed for this >70% of PCa patients who seek treatment for Gleason score 6 and 7 tumors, as determined by tumor morphology, points to an underlying weakness in the evaluation of prostate tumors, and indicates insufficient specificity in their current description. It is likely that tumor aggressiveness, a crucially informative feature that cannot now be assessed without prostatectomy, accounts for the unpredictable outcomes experienced by these patients. For most of them, decisions on treatment must be determined in the absence of information about tumor behavior and aggressiveness, and in spite of the fact that the selected course may prove to be inappropriate. Preliminary studies of high resolution magic-angle-spinning proton magnetic resonance spectroscopy (HRMAS 1HMRS) as a tool for sensitively and quantitatively probing the underlying biology and behavior of prostate tumors have produced significant results. These results support the technique's potential value for prostate cancer diagnosis and treatment planning. This proposal seeks to correlate metabolic profiles of intact prostatectomy tissue, measured by HRMAS 1HMRS, with both prostate tissue histopathological features and the clinical status of individual patients, in order to establish prostate cancer metabolic profiles and to define cancer signatures. It then aims to test the diagnostic efficacy, confirmed by histopathology, of these respective markers for predicting pathological stage and patient clinical status in both prostatectomy specimens and biopsy samples. Finally, it plans to assess longitudinally the prognostic capability of tumor metabolic profiles, independent of histopathology, to predict specific tumor behavior and patient outcome. Relevance: the overall goal of the project is to improve the accuracy of prostate cancer diagnosis, to contribute to the patient well-being, as well as to reduce costs related prostate cancer cares.
描述(由申请人提供):二十年来,PSA 检测已在临床实践中常规使用。这种强调早期发现恶性肿瘤的方法取得了巨大成功,可以通过当今前列腺癌患者群体与 20 年前的一个关键区别来判断:如今,>70% 的前列腺癌患者被诊断为无症状、中分化腺癌。尽管取得了这一成就,前列腺癌仍然是美国男性癌症死亡的第二大原因。对于格里森评分为 6 和 7 的肿瘤寻求治疗的 >70% 的 PCa 患者观察到的结果的多样性(根据肿瘤形态确定)表明前列腺肿瘤评估存在潜在的弱点,并表明目前的描述缺乏特异性。肿瘤侵袭性是一种至关重要的信息特征,如果不进行前列腺切除术就无法对其进行评估,这很可能解释了这些患者所经历的不可预测的结果。对于大多数人来说,治疗决定必须在缺乏有关肿瘤行为和侵袭性的信息的情况下做出,尽管所选择的疗程可能被证明是不合适的。高分辨率魔角旋转质子磁共振波谱(HRMAS 1HMRS)作为敏感和定量探测前列腺肿瘤的潜在生物学和行为的工具的初步研究已经产生了显着的结果。这些结果支持了该技术对于前列腺癌诊断和治疗计划的潜在价值。该提案旨在将 HRMAS 1HMRS 测量的完整前列腺切除组织的代谢特征与前列腺组织组织病理学特征和个体患者的临床状态相关联,以便建立前列腺癌代谢特征并定义癌症特征。然后旨在测试经组织病理学证实的这些各自标记物的诊断功效,以预测前列腺切除标本和活检样本中的病理阶段和患者临床状态。最后,它计划纵向评估肿瘤代谢谱的预后能力,独立于组织病理学,以预测特定的肿瘤行为和患者结果。相关性:该项目的总体目标是提高前列腺癌诊断的准确性,为患者的福祉做出贡献,并降低与前列腺癌护理相关的成本。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Leo L Cheng其他文献
Leo L Cheng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Leo L Cheng', 18)}}的其他基金
Metabolomic characterization of normal aging and Alzheimer's disease under anesthesia- surgery stimuli
麻醉手术刺激下正常衰老和阿尔茨海默病的代谢组学特征
- 批准号:
10350570 - 财政年份:2021
- 资助金额:
$ 55.73万 - 项目类别:
Metabolomic characterization of normal aging and Alzheimer's disease under anesthesia- surgery stimuli
麻醉手术刺激下正常衰老和阿尔茨海默病的代谢组学特征
- 批准号:
10556362 - 财政年份:2021
- 资助金额:
$ 55.73万 - 项目类别:
Upgrade of Console for 600 MHz MR Spectrometer
600 MHz 磁共振波谱仪控制台升级
- 批准号:
9272595 - 财政年份:2017
- 资助金额:
$ 55.73万 - 项目类别:
Development of Metabolomic and Molecular Probes for Prostate Cancer Assessment
用于前列腺癌评估的代谢组学和分子探针的开发
- 批准号:
8205493 - 财政年份:2011
- 资助金额:
$ 55.73万 - 项目类别:
Development of Metabolomic and Molecular Probes for Prostate Cancer Assessment
用于前列腺癌评估的代谢组学和分子探针的开发
- 批准号:
8332771 - 财政年份:2011
- 资助金额:
$ 55.73万 - 项目类别:
Detection of Lung Cancer Risks for Serum Metabolomics
血清代谢组学检测肺癌风险
- 批准号:
7787700 - 财政年份:2010
- 资助金额:
$ 55.73万 - 项目类别:
Detection of Lung Cancer Risks for Serum Metabolomics
血清代谢组学检测肺癌风险
- 批准号:
8010636 - 财政年份:2010
- 资助金额:
$ 55.73万 - 项目类别:
Characterizing Prostate Cancer By ex vivo MRS Signatures
通过离体 MRS 特征表征前列腺癌
- 批准号:
7914796 - 财政年份:2009
- 资助金额:
$ 55.73万 - 项目类别:
Characterizing Prostate Cancer By ex vivo MRS Signatures
通过离体 MRS 特征表征前列腺癌
- 批准号:
8530894 - 财政年份:2006
- 资助金额:
$ 55.73万 - 项目类别:
Characterizing Prostate Cancer By ex vivo MRS Signatures
通过离体 MRS 特征表征前列腺癌
- 批准号:
9248210 - 财政年份:2006
- 资助金额:
$ 55.73万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 55.73万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 55.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 55.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 55.73万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 55.73万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 55.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 55.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 55.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 55.73万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 55.73万 - 项目类别: